ClinConnect ClinConnect Logo
Search / Trial NCT05149196

Goal-directed Hemodynamic Management and Kidney Injury After Radical Nephrectomy or Nephroureterectomy

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Dec 7, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Nephrectomy Nephroureterectomy Hemodynamic Management Acute Kidney Injury Chronic Kidney Diseases

ClinConnect Summary

This clinical trial is studying how a specific type of medical management during surgery can help protect the kidneys from injury. The surgeries involved are called radical nephrectomy and nephroureterectomy, which are performed to treat certain types of kidney and urinary tract cancers. Unfortunately, many patients experience acute kidney injury after these surgeries, which can lead to long-term kidney problems. The researchers believe that a tailored approach to managing blood flow and hydration during surgery may lower the risk of kidney injury and improve overall kidney health in the long run.

To participate in this study, you need to be at least 18 years old and scheduled for one of the surgeries mentioned. However, if you have severe chronic kidney disease, uncontrolled high blood pressure, certain heart conditions, or other serious health issues, you may not be eligible. If you join the study, you can expect careful monitoring and support during your surgery to help maintain healthy kidney function. This trial aims to provide valuable insights that could improve care for future patients undergoing these surgeries.

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 1. Age of 18 years or older;
  • 2. Scheduled to undergo unilateral radical nephrectomy for renal cancer or unilateral radical nephroureterectomy for upper tract urothelial carcinoma.
  • Exclusion criteria
  • 1. Diagnosed with chronic kidney disease stage 4 or stage 5 (GFR\<30 ml/min/1.73m2) before surgery;
  • 2. Uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg);
  • 3. Combined with cardiovascular diseases with Revised Cardiac Risk Index (RCRI) \>1 or metabolic equivalents (METs) \<4;
  • 4. Unable to communicate due to severe dementia, language barrier, or end-stage disease before surgery;
  • 5. Other conditions that are considered unsuitable for inclusion (specific reasons should be indicated).

About Peking University First Hospital

Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Dong-Xin Wang, MD, PhD

Principal Investigator

Peking University First Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials